Rani Therapeutics Holdings (RANI) Share-based Compensation (2021 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Share-based Compensation of $32000.0 for Q1 2026, down 99.18% year-over-year from $3.9 million in Q1 2025, and down 99.73% quarter-over-quarter from $11.8 million in Q4 2025.
Rani Therapeutics Holdings (RANI) Share-based Compensation (2021 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Share-based Compensation history runs 6 years deep, the most recent figure standing at $32000.0 for Q1 2026.
- In Q1 2026, Share-based Compensation fell 99.18% year-over-year to $32000.0; the TTM figure through Mar 2026 stood at $31.7 million (up 13.59% YoY), while the FY2025 annual figure was $11.8 million, down 35.88% from the prior year.
- Share-based Compensation for Q1 2026 stood at $32000.0, down from $11.8 million in the prior quarter.
- The five-year high for Share-based Compensation was $21.8 million in Q3 2024, with the low at -$4.3 million in Q2 2023.
- The 5-year median for Share-based Compensation is $4.3 million (2023), against an average of $7.5 million.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation slumped 207.7% in 2023, then jumped 75072.41% in 2024.
- Rani Therapeutics Holdings' Share-based Compensation stood at $15.3 million in 2022, then grew by 23.43% to $18.8 million in 2023, then fell by 15.14% to $16.0 million in 2024, then decreased by 26.47% to $11.8 million in 2025, then sank by 99.73% to $32000.0 in 2026.
- Business Quant data shows RANI's Share-based Compensation at $32000.0 in Q1 2026, $11.8 million in Q4 2025, and $8.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | - |
| 10 | Rani Therapeutics Holdings | 165.48 Mn | 165.48 Mn | - | 11.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.90 Mn |
| Jun 30, 2026 | 11.90 Mn |
| Mar 31, 2026 | 32,000.00 |
| Mar 31, 2026 | 32,000.00 |
| Dec 31, 2025 | 11.76 Mn |
| Dec 31, 2025 | 11.76 Mn |
| Sep 30, 2025 | 8.40 Mn |
| Sep 30, 2025 | 8.40 Mn |
| Jun 30, 2025 | 2.90 Mn |
| Jun 30, 2025 | 2.90 Mn |
| Mar 31, 2025 | 3.93 Mn |
| Mar 31, 2025 | 3.93 Mn |
| Dec 31, 2024 | 15.99 Mn |
| Dec 31, 2024 | 15.99 Mn |
| Sep 30, 2024 | 21.80 Mn |
| Sep 30, 2024 | 21.80 Mn |
| Jun 30, 2024 | 4.13 Mn |
| Jun 30, 2024 | 4.13 Mn |
| Mar 31, 2024 | 3.87 Mn |
| Mar 31, 2024 | 3.87 Mn |